Drug Profile
Research programme: polyclonal antibodies - SAB Biotherapeutics
Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator SAB Biotherapeutics
- Class Antibacterials; Antineoplastics; Antivirals; Polyclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alphavirus infections; Cancer; Clostridium difficile infections; Dengue; Ebola virus infections; Hantavirus infections; Influenza virus infections; Mycoplasma infections; Viral haemorrhagic fevers; Zika virus infection
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in USA
- 11 Jun 2021 Preclinical development in Cancer is still ongoing in USA
- 28 May 2021 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in USA